Literature DB >> 29766472

Epidemiology, management and outcome of varicella in pregnancy: a 20-year experience at the Tuscany Reference Centre for Infectious Diseases in Pregnancy.

Michele Trotta1,2, Beatrice Borchi1,2, Alessandra Niccolai3, Elisabetta Venturini4,5, Susanna Giaché6, Gaetana Sterrantino1, Maria Grazia Colao7, Gian Maria Rossolini6,7, Alessandro Bartoloni1,6, Lorenzo Zammarchi8,9,10.   

Abstract

Data from 215 pregnant women exposed to varicella and 276 with varicella observed at the Tuscany Reference Center for Infectious Diseases in Pregnancy, Florence, Italy, in the period 1997-2016 were retrospectively collected. The risk of developing varicella was lower in exposed women who received varicella zoster immunoglobulin compared with those who did not receive it [42% (21 of 50) vs 72% (13 of 18); p = 0.0263]. Typical congenital varicella syndrome was observed in 1.56% of fetuses/neonates born from pregnant women with varicella.

Entities:  

Keywords:  Chickenpox; Congenital; Immunoglobulin; VZIG; Varicella; Varicella zoster virus

Mesh：

Substances：

Year:  2018        PMID： 29766472     DOI： 10.1007/s15010-018-1150-4

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   7.455


  13 in total

Review 1.  VARICELLA PNEUMONIA COMPLICATING PREGNANCY. REPORT OF A CASE AND REVIEW OF LITERATURE.

Authors:  R E HARRIS; E R RHOADES
Journal:  Obstet Gynecol       Date:  1965-05       Impact factor: 7.661

2.  Varicella-zoster infections in late pregnancy.

Authors:  G Sterner; M Forsgren; E Enocksson; M Grandien; G Granström
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 3.  Herpesviridae Infection: Prevention, Screening, and Management.

Authors:  Akila Subramaniam; William J Britt
Journal:  Clin Obstet Gynecol       Date:  2018-03       Impact factor: 2.190

Review 4.  The congenital varicella syndrome.

Authors:  A Sauerbrei; P Wutzler
Journal:  J Perinatol       Date:  2000-12       Impact factor: 2.521

5.  FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-03-30       Impact factor: 17.586

Review 6.  Congenital varicella syndrome: A systematic review.

Authors:  Ki Hoon Ahn; Yun-Jung Park; Soon-Cheol Hong; Eun Hee Lee; Ji-Sung Lee; Min-Jeong Oh; Hai-Joong Kim
Journal:  J Obstet Gynaecol       Date:  2016-03-10       Impact factor: 1.246

7.  Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women.

Authors:  James H Harger; Joseph M Ernest; Gary R Thurnau; Atef Moawad; Valerija Momirova; Mark B Landon; Richard Paul; Menachem Miodovnik; Mitchell Dombrowski; Baha Sibai; Peter Van Dorsten
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

8.  Varicella-zoster immunoglobulin treatment in pregnant women in Denmark from 2005 to 2015: descriptive epidemiology and follow-up.

Authors:  C Jespersen; I G Helmuth; T G Krause
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

9.  Impact of universal vaccination against varicella in Italy.

Authors:  Angela Bechini; Sara Boccalini; Vincenzo Baldo; Silvia Cocchio; Paolo Castiglia; Tolinda Gallo; Sandro Giuffrida; Francesco Locuratolo; Silvio Tafuri; Domenico Martinelli; Rosa Prato; Emanuele Amodio; Francesco Vitale; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Updated recommendations for use of VariZIG--United States, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-07-19       Impact factor: 17.586
View more
  3 in total

1.  Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.

Authors:  Lara J Wolfson; Vincent J Daniels; Matthew Pillsbury; Zafer Kurugöl; Cuneyt Yardimci; Jeffrey Kyle; Ener Cagri Dinleyici
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

2.  Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.

Authors:  Myron J Levin; Jennifer M Duchon; Geeta K Swamy; Anne A Gershon
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

3.  Impact of maternal nutrition in viral infections during pregnancy.

Authors:  Alfonso Mate; Claudia Reyes-Goya; Álvaro Santana-Garrido; Luis Sobrevia; Carmen M Vázquez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-07-31       Impact factor: 5.187
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.